Discovery of Potent & Selective Oral STAT3 Inhibitors with Potential Efficacy & Safety Differentiation Versus JAK/ TYK2 Targeting
Time: 2:00 pm
day: Day Two Discovery Track PM
Details:
- SH2 domain discovery platform integrating DNA-encoded libraries and crystallography enabled drug design
- Optimizing inflammatory cytokine inhibition to achieve deep and durable immune modulation
- Utilizing translational assays to explore infection and hematologic homeostasis differentiation
